These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19739966)

  • 1. Empirical versus preemptive antifungal therapy for fever during neutropenia.
    Marr KA; Leisenring W; Bow E
    Clin Infect Dis; 2009 Oct; 49(7):1138-9; author reply 1139-40. PubMed ID: 19739966
    [No Abstract]   [Full Text] [Related]  

  • 2. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin versus liposomal amphotericin B: are they really comparable?
    Sekine L; Humbwavali J; Wolff FH; Barcellos NT
    Pediatr Infect Dis J; 2010 Oct; 29(10):985-6; author reply 986-7. PubMed ID: 20859182
    [No Abstract]   [Full Text] [Related]  

  • 4. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
    Martino R; Viscoli C
    Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2001 Feb; 32(3):518-9. PubMed ID: 11170965
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 7. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
    Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antimicrobial therapy in neutropenia].
    Maschmeyer G; Vogt K; Hahn H; Dörken B
    Dtsch Med Wochenschr; 1997 Jul; 122(27):864-9. PubMed ID: 9280698
    [No Abstract]   [Full Text] [Related]  

  • 9. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
    Rieger CT; Ostermann H
    Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology].
    Link H; Blumenstengel K; Böhme A; Cornely O; Kellner O; Nowrousian MR; Ostermann H; Schiel X; Wilhelm M
    Dtsch Med Wochenschr; 1999 Apr; 124 Suppl 1():S3-8. PubMed ID: 10410648
    [No Abstract]   [Full Text] [Related]  

  • 11. Antifungal therapy for febrile neutropenia: issues in clinical trial design.
    Marr KA
    Curr Opin Investig Drugs; 2004 Feb; 5(2):202-7. PubMed ID: 15043395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
    Zinner SH
    Int J Hematol; 1998 Oct; 68 Suppl 1():S31-4. PubMed ID: 9838742
    [No Abstract]   [Full Text] [Related]  

  • 13. Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values.
    Powers JH
    Clin Infect Dis; 2004 Dec; 39(11):1738-9; author reply 1739. PubMed ID: 15578387
    [No Abstract]   [Full Text] [Related]  

  • 14. Preemptive antifungal therapy among neutropenic patients.
    Stefani PM; Gottardi M; Zanetti F; Tecchio C; Sartor D; Gherlinzoni F
    Clin Infect Dis; 2006 May; 42(10):1507-8; author reply 1508-9. PubMed ID: 16619177
    [No Abstract]   [Full Text] [Related]  

  • 15. [Infection therapy in neutropenia].
    Adam D
    Dtsch Med Wochenschr; 1999 Apr; 124 Suppl 1():S2. PubMed ID: 10410647
    [No Abstract]   [Full Text] [Related]  

  • 16. Empirical antifungal therapy in neutropenic patients.
    Cohen J
    J Antimicrob Chemother; 1984 May; 13(5):409-11. PubMed ID: 6735959
    [No Abstract]   [Full Text] [Related]  

  • 17. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008.
    Bennett JE
    J Antimicrob Chemother; 2009 May; 63 Suppl 1(Suppl 1):i23-6. PubMed ID: 19372177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy.
    de Pauw BE; Rubin RH
    Transpl Infect Dis; 2006 Mar; 8(1):1-2. PubMed ID: 16623814
    [No Abstract]   [Full Text] [Related]  

  • 19. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutropenic fever of undetermined origin (N-FUO): why not use the naproxen test?
    Chang JC; Hawley HB
    Cancer Invest; 1995; 13(4):448-50. PubMed ID: 7627730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.